George Yancopoulos, Regeneron president and CSO (Brendan McDermid/Reuters/Alamy)

George Yan­copou­los says he's on the trail of the holy grail: ‘This could rep­re­sent the next break­through for im­munother­a­py’

Two of the most out­spo­ken — and suc­cess­ful — drug de­vel­op­ers in biotech say they’ve col­lect­ed ear­ly-stage clin­i­cal da­ta that are point­ing them down the trail to the holy grail in can­cer im­munother­a­py R&D.

While an­a­lysts large­ly bus­ied them­selves to­day with chron­i­cling the on­go­ing suc­cess of Re­gen­eron’s two big cash cows — Dupix­ent and Eylea — chief sci­en­tist George Yan­copou­los and CEO Len Schleifer used the Q2 call to spot­light their ear­ly suc­cess with a com­bi­na­tion of the “home­grown” PS­MAx­CD28 cos­tim­u­la­to­ry bis­pe­cif­ic an­ti­body REGN5678 in com­bi­na­tion with their PD-1 check­point Lib­tayo. The pre­sen­ta­tion comes just weeks af­ter Re­gen­eron com­plet­ed a deal to gath­er all rights to the PD-1 that had been in Sanofi’s hands. And the two top ex­ecs are un­stint­ing in their praise of the po­ten­tial of a whole set of cos­tim­u­la­to­ry pipeline projects which they say may fi­nal­ly de­liv­er the long-await­ed next-lev­el ap­proach to broad­en­ing the im­munother­a­py field of drugs.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.